Nightingale Health has received six patent approvals for its proprietary health risk detection platform
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Nightingale Health has received six patent approvals for its proprietary health risk detection platform

{newsItem.title}

Nightingale Health Plc, Press release, 23 May 2023 at 9:00 a.m. (EEST)

Nightingale Health Plc (“Nightingale Health”), a technology company promoting preventative health with its proprietary health risk detection platform, has continued its long-term efforts regarding patenting its risk detection capabilities and, subsequently, cumulated six patent approvals from the Finnish Patent Authority during the past months.

The patents were granted for the company’s health risk detection platform’s ability to determine whether an individual is at risk of developing renal disease, atrial fibrillation, digestive system disease, and pre-eclampsia. Additionally, patents were granted for the ability to determine whether an individual is at risk of dying from breast cancer and risk of dying from prostate cancer.

The acquired patents further recognize the company’s health risk detection platform’s novel ability to determine disease risks for a variety of diseases from one blood sample. This builds on top of the company’s existing regulatory approvals and broad scientific validation.

In addition to the recently granted patents, Nightingale Health has several other patent applications pending at the Finnish Patent Authority. The company is also in the process of expanding its patents internationally.

 

For further information, please contact:

Teemu Suna, CEO
[email protected]

 

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

 

Nyheter om Nightingale Health

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Nightingale Health

Senaste nytt